EP2288622A4 - Polypeptides modifiés de facteur ix et leurs utilisations - Google Patents

Polypeptides modifiés de facteur ix et leurs utilisations

Info

Publication number
EP2288622A4
EP2288622A4 EP09743241A EP09743241A EP2288622A4 EP 2288622 A4 EP2288622 A4 EP 2288622A4 EP 09743241 A EP09743241 A EP 09743241A EP 09743241 A EP09743241 A EP 09743241A EP 2288622 A4 EP2288622 A4 EP 2288622A4
Authority
EP
European Patent Office
Prior art keywords
polypeptides
modified factor
factor
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09743241A
Other languages
German (de)
English (en)
Other versions
EP2288622A2 (fr
Inventor
Alan Brooks
John E Murphy
Marian Seto
Xiaoqiao Jiang
Chandra Patel
Uwe Gritzan
Kornelia Kirchner
Ulrich Haupts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Healthcare LLC
Original Assignee
Bayer Pharma AG
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Healthcare LLC filed Critical Bayer Pharma AG
Publication of EP2288622A2 publication Critical patent/EP2288622A2/fr
Publication of EP2288622A4 publication Critical patent/EP2288622A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP09743241A 2008-04-16 2009-04-16 Polypeptides modifiés de facteur ix et leurs utilisations Withdrawn EP2288622A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12456708P 2008-04-16 2008-04-16
US4596108P 2008-04-17 2008-04-17
PCT/US2009/040813 WO2009137254A2 (fr) 2008-04-16 2009-04-16 Polypeptides modifiés de facteur ix et leurs utilisations

Publications (2)

Publication Number Publication Date
EP2288622A2 EP2288622A2 (fr) 2011-03-02
EP2288622A4 true EP2288622A4 (fr) 2012-04-18

Family

ID=41265284

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09743241A Withdrawn EP2288622A4 (fr) 2008-04-16 2009-04-16 Polypeptides modifiés de facteur ix et leurs utilisations

Country Status (17)

Country Link
EP (1) EP2288622A4 (fr)
JP (1) JP2011517951A (fr)
KR (1) KR20110005862A (fr)
CN (1) CN102083856A (fr)
AU (1) AU2009244633A1 (fr)
BR (1) BRPI0910702A2 (fr)
CA (1) CA2721683A1 (fr)
CO (1) CO6311000A2 (fr)
CR (1) CR11737A (fr)
DO (1) DOP2010000311A (fr)
EC (1) ECSP10010551A (fr)
IL (1) IL208718A0 (fr)
MX (1) MX2010011345A (fr)
RU (1) RU2010146387A (fr)
SG (1) SG189790A1 (fr)
SV (1) SV2010003704A (fr)
WO (1) WO2009137254A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423306A1 (fr) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Polypeptides du facteur IX à coagulation modifiée et leur utilisation pour le traitement
CN104004739A (zh) * 2007-10-15 2014-08-27 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ix变体
FI3581650T3 (fi) 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
NZ605348A (en) 2010-07-09 2015-01-30 Biogen Idec Hemophilia Inc Factor ix polypeptides and methods of use thereof
AU2013204511B2 (en) * 2010-11-03 2016-03-17 Gc Biopharma Corp. Modified factor ix polypeptides and uses thereof
TWI595004B (zh) * 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
SI2717898T1 (sl) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Spojine prokoagulantov in metode za njihovo uporabo
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
WO2013162078A1 (fr) * 2012-04-27 2013-10-31 学校法人日本大学 Agent thérapeutique pour une lésion dans un épithélium et un endothélium
EP3970738A1 (fr) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Essai de surveillance de facteur sanguin et utilisations de celui-ci
US20150252345A1 (en) 2012-09-25 2015-09-10 Biogen Idec Ma Inc. Methods of Using FIX Polypeptides
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
ES2959747T3 (es) 2013-02-15 2024-02-28 Bioverativ Therapeutics Inc Gen del factor VIII optimizado
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
HUE057005T2 (hu) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc Oszlopon történõ vírusinaktiváló eljárások
WO2015070014A1 (fr) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Composé de fusion procoagulant
EP4332839A3 (fr) 2013-12-06 2024-06-05 Bioverativ Therapeutics Inc. Outils pharmacocinétiques de population et leurs utilisations
EP3083933A1 (fr) 2013-12-20 2016-10-26 Biogen MA Inc. Utilisation de cultures de semences sous perfusion pour améliorer la capacité de production en alimentation programmée de produits biopharmaceutiques et la qualité des produits
EP3123090A4 (fr) 2014-03-24 2017-12-13 Bioverativ Therapeutics Inc. Formulations de facteur ix lyophilisées
WO2016004113A1 (fr) 2014-06-30 2016-01-07 Biogen Ma Inc. Gène du facteur ix optimisé
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
HRP20221089T1 (hr) 2016-02-01 2022-11-25 Bioverativ Therapeutics Inc. Optimizirani geni faktora viii
CN105695616A (zh) * 2016-04-22 2016-06-22 王冬国 诊断甲状腺癌的分析标志物及其应用
EP3548066A1 (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
AU2018215092A1 (en) 2017-01-31 2019-08-29 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
FR3069540B1 (fr) 2017-07-28 2019-09-13 Universite Claude Bernard Lyon 1 Proteine modifiee avec demi-vie amelioree
US20210163986A1 (en) 2017-08-09 2021-06-03 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US20200263196A1 (en) 2017-09-27 2020-08-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
RU2020136050A (ru) 2018-04-04 2022-05-06 Сайджилон Терапьютикс, Инк. Имплантируемые частицы и соответствующие способы
WO2019195056A1 (fr) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Procédés, compositions et éléments implantables comprenant des cellules souches
JP2021523878A (ja) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
US20200069817A1 (en) 2018-08-09 2020-03-05 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2020086408A1 (fr) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bioprocédé d'expression génique transitoire basé sur une perfusion à haut rendement
JP2022531095A (ja) 2019-04-17 2022-07-06 コディアック バイオサイエンシーズ， インコーポレイテッド エキソソーム及びａａｖの組成物
WO2021154414A2 (fr) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Thérapie génique pour l'hémophilie b avec un vecteur de capside d'aav chimérique codant pour des polypeptides du facteur ix modifiés
EP4298737A1 (fr) 2021-02-24 2024-01-03 BlueHalo LLC Système et procédé d'alimentation de réseau à commande de phase à formation de faisceau numérique
WO2024081310A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie
WO2024081309A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007149406A2 (fr) * 2006-06-19 2007-12-27 Nautilus Technology Llc Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
WO1999003496A1 (fr) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Facteur ix antihemophilique presentant une activite de coagulation augmentee
EP1427820A2 (fr) * 2001-09-04 2004-06-16 MERCK PATENT GmbH Facteur ix modifie
MXPA05010846A (es) * 2003-04-09 2006-03-30 Nektar Therapeutics Tratamiento de hemofilia mediante inhalacion de factores de coagulacion.
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
BRPI0417341A (pt) * 2003-12-03 2007-04-17 Neose Technologies Inc fator ix glicopeguilado
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007149406A2 (fr) * 2006-06-19 2007-12-27 Nautilus Technology Llc Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique

Also Published As

Publication number Publication date
CO6311000A2 (es) 2011-08-22
BRPI0910702A2 (pt) 2016-07-05
SG189790A1 (en) 2013-05-31
CA2721683A1 (fr) 2009-11-12
EP2288622A2 (fr) 2011-03-02
RU2010146387A (ru) 2012-05-27
IL208718A0 (en) 2010-12-30
SV2010003704A (es) 2011-02-21
KR20110005862A (ko) 2011-01-19
CR11737A (es) 2011-02-07
MX2010011345A (es) 2011-02-23
DOP2010000311A (es) 2011-02-28
WO2009137254A3 (fr) 2010-01-14
ECSP10010551A (es) 2010-11-30
AU2009244633A1 (en) 2009-11-12
JP2011517951A (ja) 2011-06-23
WO2009137254A2 (fr) 2009-11-12
CN102083856A (zh) 2011-06-01

Similar Documents

Publication Publication Date Title
IL208718A0 (en) Modified factor ix polypeptides and uses thereof
IL225740A0 (en) Adapted factor vii polypeptides and uses thereof
IL237314A0 (en) Modified insulin polypeptides and their uses
IL218776A0 (en) Modified factor vii polypeptides and uses thereof
ZA201200716B (en) Modified factor ix polypeptides and uses thereof
ZA201303134B (en) Modified factor ix polypeptides and uses thereof
IL207096A0 (en) Modified leptin polypeptides and their uses
IL210804A (en) Benzylidenehydrazides and their uses
GB0916578D0 (en) Polypeptides and uses thereof
IL210265A0 (en) Modified bovine g - csf polypeptides and their uses
GB0916576D0 (en) Polypeptides and uses thereof
EP2483292A4 (fr) Polypeptides lovd variants et leurs utilisations
GB0708376D0 (en) Novel polypeptides and uses thereof
ZA201103456B (en) Leukolectins and uses thereof
EP2291377A4 (fr) Imidazopyrimidinones et leurs utilisations
EP2247601A4 (fr) Thiazopyrimidinones et leurs utilisations
EP2285827A4 (fr) Peptides et leurs utilisations
GB0905790D0 (en) Novel polypeptides and use thereof
GB0800698D0 (en) F2 polypeptides and usesthereof
GB0800701D0 (en) F10 Polypeptides and uses thereof
GB0800700D0 (en) F9 polypeptides and uses thereof
GB0816561D0 (en) Peptides and uses thereof
GB0800502D0 (en) Peptides and their uses
AU2008902600A0 (en) Polypeptides and uses thereof
GB0800699D0 (en) F7 polypeptides and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101116

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HAUPTS, ULRICH

Inventor name: KIRCHNER, KORNELIA

Inventor name: GRITZAN, UWE

Inventor name: PATEL, CHANDRA

Inventor name: JIANG, XIAOQIAO

Inventor name: SETO, MARIAN

Inventor name: MURPHY, JOHN, E.

Inventor name: BROOKS, ALAN

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT

Owner name: BAYER HEALTHCARE LLC

A4 Supplementary search report drawn up and despatched

Effective date: 20120316

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/64 20060101ALI20120312BHEP

Ipc: C07K 14/745 20060101AFI20120312BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER HEALTHCARE, LLC

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT

17Q First examination report despatched

Effective date: 20140613

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141024